2024 Cell and Gene Therapy Summit

Presentations and Panel Sessions

FDA’s Focus for 2024 & Beyond: Cell and Gene Therapies | Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration

Genomic and Phenotypic Predictors of Human Ex Vivo Sensitivity to Simulated Deep Space Radiation | Dr. Sylvain Costes, Space Biosciences Branch Chief at NASA Ames and the Project Manager for Open Science for Space Biology (GeneLab/ALSDA)

Patient Story | Nasha Fitter, CEO, FOXG1 Research Foundation / Co-Founder and CBO, Ciitizen
The FOXG1 Research Foundation (FRF) is the parent-led, global rare disease patient organization driving the research to find successful and precise treatments, and ultimately a cure, for every individual in the world with FOXG1 syndrome, while deeply focusing on patient advocacy, education, and family support.

Viral Vector Gene Therapy Journey (from Discovery to Commercialization) | Moderator: James Cody, Charles River

In the rapidly maturing advanced therapies field, viral vectors continue to play a fundamental role. Take a trip through the Viral Vector Gene Therapy Journey from concept to cure, covering common challenges and critical considerations, and gain valuable insights from experts with hands-on experience across the breadth of the vector-based gene therapy development pathway.

• Chris Mason, Professor, University College London
• Jordan Jarjour, CSO, Moonlight Bio
• Nallakkan Arvindan, CTO, Walking Fish
• Sandra Nino, Vice President of Regulatory Strategy, Ultragenyx
• Richard Wilson, SVP, Primary Focus Lead, Genetic Regulation, Astellas

CAR-T Therapy Journey (from Discovery to Commercialization) | Moderator: Alex Sargent, Charles River

The path to market starts at the very beginning. Developing a commercialization strategy while in the discovery phase allows for anticipation of market approvals, tech transfer, and other late-phase challenges that can impact cost and time to GMP. Join our Cell Therapy Journey panel to hear from experts on how to successfully navigate your drug therapy development from discovery to commercialization.

• Aaron Foster, CSO, Outpace Bio
• Wendell Lim, PhD, Byers Distinguished Professor, Department of Cellular & Molecular Pharmacology, Director UCSF Cell Design Institute, University of California San Francisco
• Jeff Holder, PhD, Managing Director, L.E.K Consulting
• Adam Haskett, Head of External Manufacturing, Cargo Therapeutics

Investor & Market Insights | Moderator: Ramin Baghirzade, Charles River

With an increasingly complex investment landscape, there is more pressure than ever on cell and gene therapy developers to differentiate themselves. This panel explores the current investor climate and future trends, and uncovers decision-making criteria and data points to be mindful of when preparing for fundraising.

• Amit Agarwal, Managing Director, Deloitte
• Carl Schoellhammer, Managing Director, DeciBio BroadOak BioTools Venture Fund
• Carolyn Ng, Partner and Managing Director, TPG Life Sciences Innovations
• Katy Spink, COO & Managing Partner at Dark Horse Consulting Inc
• Ahmed Mousa, Managing Director, Tamer Life Science

Company Pitches

Elevating the elevator pitch, this session showcases the “who, what, why, and how” direct from the C-Suite and highlights technologies, milestones, path to clinic, and patient outcomes in an easily digestible format.

• Amber Salzman, CEO, Epic Bio
• Konstantin Kazarian, CEO, Hybrid Bio
• Chris Lorenz, CTO, Mahzi Therapeutics
• Christopher Potts, CEO, Monarch Therapeutics
• Samarendra Mohanty, President and CSO, Nanoscope
• Ana Moreno, CEO, Navega Therapeutics
• Noah Auerhahn, Founder & CEO, Uncommon Therapeutics
• Will Pedranti, CEO, VisgenX Therapeutics
• Loretto Callaghan, CEO, Vzarii Therapeutics